Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geert D'Haens

Showing results (81-90 of 269) with videos related to

Pageof 27
Sort By:
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
United European Gastroenterology Journal|November 9, 2019
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®<sup>MMX®</sup>) for active, mild-to-moderate ulcerative colitisSilvio Danese, Ailsa Hart, Axel Dignass, et al.
Expert Review of Clinical Pharmacology|March 5, 2024
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitisGeert D'Haens, Maria Rosario, Daniel Polhamus, et al.
Journal of Crohn'S & Colitis|March 24, 2026
Transperineal ultrasonography in detecting penetrating perianal disease: a systematic review and meta-analysisChong-Teik Lim, Maarten Pruijt, Gek-Hsiang Lim, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 19, 2021
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisSteven J Bots, Claire E Parker, Johannan F Brandse, et al.
Gut|September 28, 2011
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGert Van Assche, Séverine Vermeire, Vera Ballet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2013
Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's diseaseJean-Frédéric Colombel, William J Sandborn, Matthieu Allez, et al.
Advances in Therapy|November 28, 2025
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy ParticipantsYuki Otani, Christopher D Payne, Edward V Loftus, et al.
Crohn'S & Colitis 360|August 28, 2023
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE StudiesWilliam J Sandborn, Jingjing Chen, Krisztina Kisfalvi, et al.
Pageof 27

Showing results (81-90 of 269) with videos related to

Sort By:
Pageof 27
The Lancet. Gastroenterology & Hepatology|June 20, 2020
Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint studyBrian G Feagan, William J Sandborn, Silvio Danese, et al.
United European Gastroenterology Journal|November 9, 2019
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®<sup>MMX®</sup>) for active, mild-to-moderate ulcerative colitisSilvio Danese, Ailsa Hart, Axel Dignass, et al.
Expert Review of Clinical Pharmacology|March 5, 2024
Exposure-efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn's disease and ulcerative colitisGeert D'Haens, Maria Rosario, Daniel Polhamus, et al.
Journal of Crohn'S & Colitis|March 24, 2026
Transperineal ultrasonography in detecting penetrating perianal disease: a systematic review and meta-analysisChong-Teik Lim, Maarten Pruijt, Gek-Hsiang Lim, et al.
Inflammatory Bowel Diseases|February 13, 2019
Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID RegistryEdward V Loftus, Walter Reinisch, Remo Panaccione, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|November 19, 2021
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-AnalysisSteven J Bots, Claire E Parker, Johannan F Brandse, et al.
Gut|September 28, 2011
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGert Van Assche, Séverine Vermeire, Vera Ballet, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2013
Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's diseaseJean-Frédéric Colombel, William J Sandborn, Matthieu Allez, et al.
Advances in Therapy|November 28, 2025
One Subcutaneous 2-ml Injection of Mirikizumab is Bioequivalent to Two 1-ml Subcutaneous Injections in Healthy ParticipantsYuki Otani, Christopher D Payne, Edward V Loftus, et al.
Crohn'S & Colitis 360|August 28, 2023
Practical Primer Addressing Real-World Use Scenarios of Subcutaneous Vedolizumab in Ulcerative Colitis and Crohn's Disease: Post Hoc Analyses of VISIBLE StudiesWilliam J Sandborn, Jingjing Chen, Krisztina Kisfalvi, et al.
Pageof 27